Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in CHRS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.4M | $17.5M | -1.9% | 8.467% | 0.00% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 5.5M | $9.2M | β | 4.455% | 0.00% |
| 3 | Samsara BioCapital, LLC | 3.4M | $5.8M | β | 2.801% | 0.56% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 3.1M | $5.3M | +13.7% | 2.550% | 0.00% |
| 5 | Kohlberg Kravis Roberts & Co. L.P. | 3.0M | $5.1M | 0.0% | 2.480% | 0.09% |
| 6 | STATE STREET CORP | 2.3M | $3.9M | +4.6% | 1.900% | 0.00% |
| 7 | TWO SIGMA INVESTMENTS, LP | 2.3M | $3.9M | +356.9% | 1.881% | 0.00% |
| 8 | Alyeska Investment Group, L.P. | 2.3M | $3.8M | β | 1.838% | 0.01% |
| 9 | CM Management, LLC | 2.1M | $3.5M | 0.0% | 1.716% | 2.97% |
| 10 | TANG CAPITAL MANAGEMENT LLC | 1.9M | $3.2M | -30.8% | 1.541% | 0.16% |
| 11 | Hudson Bay Capital Management LP | 1.7M | $2.9M | +104.2% | 1.393% | 0.03% |
| 12 | PANAGORA ASSET MANAGEMENT INC | 1.5M | $2.5M | -9.9% | 1.192% | 0.01% |
| 13 | Propel Bio Management, LLC | 1.4M | $2.4M | β | 1.161% | 1.52% |
| 14 | AQR CAPITAL MANAGEMENT LLC | 1.2M | $2.0M | +36.2% | 0.985% | 0.00% |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.2M | $2.0M | +23.6% | 0.944% | 0.00% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 950K | $1.6M | β | 0.776% | 0.00% |
| 17 | NORTHERN TRUST CORP | 914K | $1.5M | +15.2% | 0.747% | 0.00% |
| 18 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 900K | $1.5M | 0.0% | 0.735% | 0.00% |
| 19 | GOLDMAN SACHS GROUP INC | 696K | $1.2M | +126.7% | 0.569% | 0.00% |
| 20 | VANGUARD PORTFOLIO MANAGEMENT LLC | 605K | $1.0M | β | 0.494% | 0.00% |
| 21 | UBS Group AG | 547K | $925K | -10.4% | 0.447% | 0.00% |
| 22 | SEI INVESTMENTS CO | 454K | $767K | +492.2% | 0.371% | 0.00% |
| 23 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 441K | $745K | 0.0% | 0.360% | 0.01% |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 415K | $701K | +8.5% | 0.339% | 0.00% |
| 25 | CITADEL ADVISORS LLC | 393K | $664K | β | 0.321% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in CHRS β a direct measure of their conviction.
Filings activity in CHRS during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 154 | +21% | 55.94% | +15.77 pp | $96M | +39% |
| Q4 2025 | 127 | +15% | 40.17% | 7.04 pp | $69M | 15% |
| Q3 2025 | 110 | 0.9% | 47.21% | +24.66 pp | $81M | +109% |
| Q2 2025 | 111 | 5.9% | 22.55% | 5.54 pp | $39M | 20% |
| Q1 2025 | 118 | 4.1% | 28.09% | 24.03 pp | $48M | 46% |
| Q4 2024 | 123 | 3.9% | 52.12% | 130.77 pp | $89M | 72% |
| Q3 2024 | 128 | 3.8% | 182.89% | +108.56 pp | $313M | +146% |
| Q2 2024 | 133 | β | 74.33% | β | $127M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying CHRS stock.
Based on Q1 2026 13F filings, institutional ownership of Coherus Oncology, Inc. stands at 55.9%, held across 154 reporting institutions.
BlackRock, Inc. is the largest reported institutional holder of CHRS, with approximately 10,365,074 shares worth $0.02B as of Q1 2026.
Yes β 3 widely-followed marquee investors appear among the top 25 institutional holders of CHRS, including TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CITADEL ADVISORS LLC.
Our composite Smart Money Score for CHRS is 82 out of 100 (Strong Smart Money). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
43 institutions opened new positions in CHRS during Q1 2026, while 16 fully exited. 93 added to existing positions and 16 trimmed.
CHRS institutional ownership rose by 15.77 percentage points quarter-over-quarter, with a net change of +27 holders.
The top 10 institutions account for 63.9% of all reported 13F value in CHRS, and the top 25 account for 87.3%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Coherus Oncology, Inc. (CHRS) Institutional Ownership